Resumen de SEOM clinical guidelines for endometrial cancer (2017)

Ana Santaballa Bertrán, Xavier Matías-Guiu Guía, A. Redondo Sánchez, Natalia Carballo González, M. Gil Martin, César Gómez Raposo, Mikel Gorostidi Pulgar, Maria Gutierrez Toribio, Antonio González Martín

• Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.